SB939 is an inhibitor of class I, II, and IV histone deacetylases (HDACs) that exhibits anticancer chemotherapeutic, anti-parasitic, and antimalarial activities. SB939 decreases tumor growth in animal models of colorectal cancer. This compound also suppresses Plasmodium growth in vitro and in vivo and prevents malaria infection.
| Cas No. | 929016-96-6 |
|---|---|
| Purity | ≥98% |
| Formula | C20H30N4O2 |
| Formula Wt. | 358.49 |
| IUPAC Name | (2E)-3-{2-Butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide |
| Synonym | SB939, Pracinostat |
| Solubility | DMSO Solubility: 72 mg/mL (200.84 mM) |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Zorzi AP, Bernstein M, Samson Y, et al. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium. Pediatr Blood Cancer. 2013 Nov;60(11):1868-74. PMID: 23893953.
Sumanadasa SD, Goodman CD, Lucke AJ, et al. Antimalarial activity of the anticancer histone deacetylase inhibitor SB939. Antimicrob Agents Chemother. 2012 Jul;56(7):3849-56. PMID: 22508312.
Novotny-Diermayr V, Sangthongpitag K, et al. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther. 2010 Mar;9(3):642-52. PMID: 20197387.
